Selenoprotein and antioxidant genes and the Riskof high-grade prostate cancer and prostate cancer recurrence

Prostate

Volumn 75, Issue 1, 2015, Pages 60-69

  Gerstenberger, John P ^a   Bauer, Scott R ^a   Van Blarigan, Erin L ^a   Sosa, Eduardo ^b   Song, Xiaoling ^c   Witte, John S ^a,b,d   Carroll, Peter R ^a,d   Chan, June M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetic polymorphisms; Gleason grade; Selenium

Indexed keywords

8 OXOGUANINE GLYCOSYLASE; CATALASE; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 3; MANGANESE SUPEROXIDE DISMUTASE; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; PROTEIN; SELENBP1 PROTEIN; SELENIUM; SELENOPROTEIN; SEP15 PROTEIN; SEPP1 PROTEIN; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2; UNCLASSIFIED DRUG; ANTIOXIDANT; TUMOR MARKER;

ADULT; ALLELE; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; SELENIUM BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK; STATISTICAL MODEL; TUMOR RECURRENCE;

AGED; ANTIOXIDANTS; BIOMARKERS, TUMOR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK; SELENIUM; SELENOPROTEINS;

EID: 84918822993     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22892     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (1): 9-29.
2. Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, Vieira R, Collings R, Harvey LJ, Sterne JA, Beynon R, Savovic J, Fairweather-Tait SJ. Selenium and prostate cancer: Systematic review and meta-analysis. Am J Clin Nutr 2012; 96 (1): 111-122.
3. Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: A systematic review and meta-analysis. Cancer Causes Control 2005; 16 (9): 1125-1131.
4. Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP. Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 2006; 42 (15): 2463-2471.
5. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MPA, Horneber M. Selenium for preventing cancer. Cochrane Database Syst Rev 2011; (5): CD005195.
6. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Slate EH, Fischbach LA, Marshall JR, Clark LC. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11 (7): 630-639.
7. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. JAMA Am Med Assoc 2009; 301 (1): 39-51.
8. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst 2014; 106 (3): djt456.
9. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: Synthesis, identity, and their role in human health. Antioxid Redox Signal 2007; 9 (7): 775-806.
10. Papp LV, Holmgren A, Khanna KK. Selenium and selenoproteins in health and disease. Antioxid Redox Signal 2010; 12 (7): 793-795.
11. Geybels MS, van den Brandt PA, Schouten LJ, van Schooten FJ, van Breda SG, Rayman MP, Green FR, Verhage BAJ. Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer. J Natl Cancer Inst 2014; 106 (3): dju003.
12. Geybels MS, Hutter CM, Kwon EM, Ostrander EA, Fu R, Feng Z, Stanford JL, Peters U. Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate 2013; 73 (7): 734-742.
13. Steinbrecher A, Méplan C, Hesketh J, Schomburg L, Endermann T, Jansen E, Akesson B, Rohrmann S, Linseisen J. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiology Biomarkers & Prevention 2010; 19 (11): 2958-2968.
14. Arsova-Sarafinovska Z, Matevska N, Eken A, Petrovski D, Banev S, Dzikova S, Georgiev V, Sikole A, Erdem O, Sayal A, Aydin A, Dimovski AJ. Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk. Int Urol Nephrol 2009; 41 (1): 63-70.
15. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, Mucci LA, Hunter DJ, Kantoff PW, Stampfer MJ, Ma J. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) 2010; 3 (5): 604-610.
16. Méplan C, Rohrmann S, Steinbrecher A, Schomburg L, Jansen E, Linseisen J, Hesketh J. Polymorphisms in thioredoxin reductase and selenoprotein k genes and selenium status modulate risk of prostate cancer. PLoS ONE 2012; 7 (11): e48709.
17. Ding WX, Ni HM, Gao W, Chen X, Kang JH, Stolz DB, Liu J, Yin XM. Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther 2009; 8 (7): 2036-2045.
18. Grundmark B, Zethelius B, Garmo H, Holmberg L. Serum levels of selenium and smoking habits at age 50 influence long term prostate cancer risk; a 34 year ULSAM follow-up. BMC Cancer 2011; 11: 431.
19. Ergen HA, Narter F, Timirci O, Isbir T. Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: A case-control study. Anticancer Res 2007; 27 (2): 1227-1230.
20. Eken A, Erdem O, Arsova-Sarafinovska Z, Akay C, Sayal A, Matevska N, Suturkova L, Erten K, Ozgök Y, Dimovski A, Aydin A. Association between gene polymorphism of manganese superoxide dismutase and prostate cancer risk. J Biochem Mol Toxicol 2013; 27 (3): 213-218.
21. Kang D, Lee K-M, Park SK, Berndt SI, Peters U, Reding D, Chatterjee N, Welch R, Chanock S, Huang W-Y, Hayes RB. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 2007; 16 (8): 1581-1586.
22. Cooper ML, Adami H-O, Grönberg H, Wiklund F, Green FR, Rayman MP. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 2008; 68 (24): 10171-10177.
23. Ding G, Liu F, Shen B, Feng C, Xu J, Ding Q. The association between polymorphisms in prooxidant or antioxidant enzymes (myeloperoxidase, SOD2, and CAT) and genes and prostate cancer risk in the Chinese population of Han nationality. Clin Genitourin Cancer 2012; 10 (4): 251-255.
24. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 2011; 107 (1): 126-134.
25. Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM. Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. Prostate 2013; 73 (16): 1786-1795.
26. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 2009; 27 (22): 3577-3583.
27. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005; 65 (6): 2498-2504.
28. Ericson SP, McHalsky ML, Rabinow BE, Kronholm KG, Arceo CS, Weltzer JA, Ayd SW. Sampling and analysis techniques for monitoring serum for trace elements. Clin Chem 1986; 32 (7): 1350-1356.
29. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS. Carotene and Retinol Efficacy Trial Co-Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10 (10): 1069-1076.
30. Rudolph RE, Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus. J Natl Cancer Inst 2003; 95 (10): 750-757.
31. Takata Y, Kristal AR, King IB, Song X, Diamond AM, Foster CB, Hutter CM, Hsu L, Duggan DJ, Langer RD, Petrovitch H, Shikany JM, Vaughan TL, Lampe JW, Prentice RL, Peters U. Serum selenium, genetic variation in selenoenzymes, and risk of colorectal cancer: Primary analysis from the Women's Health Initiative Observational Study and meta-analysis. Cancer Epidemiology Biomarkers & Prevention 2011; 20 (9): 1822-1830.
32. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA Am Med Assoc 1998; 280 (11): 969-974.
33. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011; 117 (22): 5039-5046.
34. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Chane Du J, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173 (6): 1938-1942.
35. Urig S, Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 2006; 16 (6): 452-465.
36. Cai W, Zhang L, Song Y, Wang B, Zhang B, Cui X, Hu G, Liu Y, Wu J, Fang J. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic Biol Med 2012; 52 (2): 257-265.
37. Kumaraswamy E, Malykh A, Korotkov KV, Kozyavkin S, Hu Y, Kwon SY, Moustafa ME, Carlson BA, Berry MJ, Lee BJ, Hatfield DL, Diamond AM, Gladyshev VN. Structure-expression relationships of the 15-kDa selenoprotein gene. Possible role of the protein in cancer etiology. J Biochem 2000; 275 (45): 35540-35547.
38. Longnecker MP, Stram DO, Taylor PR, Levander OA, Howe M, Veillon C, McAdam PA, Patterson KY, Holden JM, Morris JS, Swanson CA, Willett WC. Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiology 1996; 7 (4): 384-390.